Kronos Bio (NASDAQ:KRON – Get Free Report) and Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 24.4% of Kronos Bio shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Kronos Bio and Chemomab Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kronos Bio | $6.29 million | 7.91 | -$112.67 million | ($1.74) | -0.47 |
| Chemomab Therapeutics | N/A | N/A | -$24.22 million | ($1.14) | -1.29 |
Volatility & Risk
Kronos Bio has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Kronos Bio and Chemomab Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kronos Bio | 0 | 0 | 2 | 0 | 3.00 |
| Chemomab Therapeutics | 0 | 0 | 3 | 1 | 3.25 |
Kronos Bio presently has a consensus price target of $4.13, suggesting a potential upside of 400.00%. Chemomab Therapeutics has a consensus price target of $5.67, suggesting a potential upside of 285.49%. Given Kronos Bio’s higher probable upside, equities analysts plainly believe Kronos Bio is more favorable than Chemomab Therapeutics.
Profitability
This table compares Kronos Bio and Chemomab Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kronos Bio | -1,222.83% | -68.82% | -51.52% |
| Chemomab Therapeutics | N/A | -102.80% | -76.79% |
Summary
Kronos Bio beats Chemomab Therapeutics on 7 of the 13 factors compared between the two stocks.
About Kronos Bio
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.
